Boehringer Ingelheim has acquired drug discovery and ... new cancer treatment combination opportunities. “This brings us a ...

October 1, 2024–Celebrate the magnificence of horses during Horse Week 2024, an online film festival proudly presented by ...

Progressive pulmonary fibrosis (PPF) is an increasingly recognised condition, defined in 2022 to address the progression of ...

A persistent, often progressive, lung disease, COPD results from chronic inflammation that leads to structural changes ...

Notable Labs’ attempts to take a Boehringer Ingelheim cancer drug to market appear to have come to end with the ...

The U.S. Food and Drug Administration has approved Elanco Animal Health's oral drug to protect dogs against six parasitic ...

German family-owned pharma major Boehringer Ingelheim and USA-based Circle Pharma (have entered into a research collaboration and license agreement with the shared goal to develop a first-in-class ...

Boehringer Ingelheim, a biopharmaceutical company active in both human and animal health, in partnership with WHO Foundation, today pledged USD 5 million to advance access to quality healthcare servic ...

The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for survodutide (BI 456906), which is ...

Hosted by Boehringer Ingelheim, the ‘CRM Summit’, an expert engagement forum, and the ‘IMETA CRM Discussions for EXperts ...

INGELHEIM, Germany and SOUTH SAN FRANCISCO, CA, USA I October 09, 2024 I Boehringer Ingelheim and Circle Pharma (Circle) announce a new research collaboration ...